The hepatitis C virus (HCV) can cause liver cancer and other dangerous liver conditions, especially in people whose immune systems are compromised by the HIV virus.

According to the latest World Health Organization estimates, 71 million people have chronic HCV infection, and almost three million people are co-infected with HIV and HCV.

Unitaid has invested more than US$48 million into fighting this blood-borne co-infection, which in most cases can be cured by direct-acting antiviral drugs in 12 weeks.

**Unitaid is partnering with:**

**Coalition PLUS**

in Brazil, Colombia, Morocco, India, Indonesia and formerly Thailand and Malaysia (until 2018). The US$10 million project (2015-2020) is stimulating demand for HCV care by raising awareness through civil society organizations and national decision makers.

**Foundation for Innovative New Diagnostics (FIND)**

The US$30 million project (2016-2020) is contributing to the Global Viral Hepatitis Strategy by introducing new and simpler HCV diagnostic tests, establishing new models for screening and treatment for people co-infected with HCV and HIV, and devising cost-reduction strategies.

**Médecins Sans Frontières (MSF) International**

This completed project developed and tested simplified, adapted and affordable care models for HCV. The results will help shape guidelines for screening and treatment of HCV. The US$8 million project took place 2015-2018.

**Medicines Patent Pool (MPP)**

Unitaid funds the MPP, which negotiates voluntary licenses for HCV medicines. The work cuts costs by enabling production and supply of generic medicines.

Unitaid’s main donors are France, the United Kingdom, Norway, the Bill & Melinda Gates Foundation, Brazil, Spain, the Republic of Korea, and Chile.